Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM4B | O94953 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17186359 | 0.98 | PDPK1 (0.40) | PDPK1PNPLMNAKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL17186229 | 0.98 | PDPK1 (0.40) | PDPK1PNPLMNAKDM4EALDH1A1 | |
| SCHEMBL22524079 | 0.84 | ALDH1A1 (0.36) | PDPK1PNPALDH1A1KDM4AKDM4B | |
| SCHEMBL17373198 | 0.79 | ALDH1A1 (0.33) | PDPK1LMNAKDM4EALDH1A1HPGD | |
| SCHEMBL8278860 | 0.77 | PARP1 (0.43) | PDPK1PNPKDM4EALDH1A1PARP1 | |
| SCHEMBL30369209 | 0.74 | GDA (0.35) | PDPK1PNPLMNAKDM4EALDH1A1 | |
| SCHEMBL28969 | 0.74 | PDPK1 (0.41) | PDPK1PNPLMNAKDM4EALDH1A1 | |
| SCHEMBL30139079 | 0.73 | PDPK1 (0.33) | PDPK1PNPKDM4AKDM4BKDM5C | |
| Guanine SCHEMBL4658042 | 0.73 | ALDH1A1 (0.61) | PNPLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL21896056 | 0.73 | PNP (0.41) | PDPK1PNPLMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| CN-115367745-B | Tungsten-containing substance hybridization and nitrogen-doped porous carbon material and preparation method thereof | 北京化工大学 | 2023-11-24 | — | — | CN | claimed |
| WO-2023126758-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2023-07-06 | — | — | WO | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| CN-115367745-A | Tungsten-containing substance hybrid and nitrogen-doped porous carbon material and preparation method thereof | 北京化工大学 | 2022-11-22 | — | — | CN | claimed |
| CN-115367726-A | Oxygen-doped titanium nitride hybridized and nitrogen-doped porous carbon material and preparation method and application thereof | 北京化工大学 | 2022-11-22 | — | — | CN | claimed |
| US-20220282275-A1 | G-TO-T BASE EDITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-09-08 | — | — | US | claimed |
| WO-2021238912-A1 | TRANSITION METAL COMPOUND-HYBRIDIZED AND NITROGEN-DOPED POROUS CARBON MATERIAL AND PREPARATION METHOD THEREFOR | 北京化工大学 | 2021-12-02 | — | — | WO | claimed |
| CN-111892047-A | Vanadium nitride hybrid and nitrogen-doped porous carbon material and preparation method and application thereof | 北京化工大学 | 2020-11-06 | — | — | CN | claimed |
| CN-1846674-A | Slow released anticancer injection | JINAN SHUIHUA MEDICINE SCI TEC (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1733306-A | Anticancer implantation agent containing blood vessel inhibitor and guanine similarities | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | claimed |
| CN-1679947-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1679944-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1679951-A | Medicinal composition for tumor body | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1679945-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1679946-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1679936-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1628852-A | Anti solid tumor medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | claimed |
| US-20040009602-A1 | DNA modifying molecules and methods of use thereof | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | PDPK1 1413/4885PNP 241/4885LMNA 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.